The firm is interested in providing financial services, information technology, and venture capitals. The firm looks to be a global presence, and is a sub-organization of Temasek Holdings. The firm has raised a single venture fund for Vertex Master Fund II, and helped raise $730 million for the company. The firm has made investments in companies such as Visterra.
A company developing antibody-based biological medicines for kidney diseases and other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018.